Skip to main content
BDSX
NASDAQ Industrial Applications And Services

Biodesix Q3 Revenue Misses, Full-Year 2026 Guidance Cut to $101M-$103M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$18.7
Mkt Cap
$209.334M
52W Low
$5.26
52W High
$31.97
52W Position info
256% above low
Off High info
42% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

BDSX has more than doubled off its 52-week low of $5.26.

Summary

Biodesix posted Q3 revenue of $24.0 million, about 13% below the $27.5 million estimate, and cut full-year 2026 revenue guidance to $101 million-$103 million. Management blames sales-rep staffing and project timing, not demand, and points to a stronger October.

Updates

  1. · Benzinga — Biodesix shares fell 29.44% to $14 in after-hours trading after the Q3 revenue miss and guidance cut.


Key Events · Earnings and Guidance · BDSX

  • Q3 Revenue Misses Consensus

    Total revenue of $24.041 million rose 10% year over year but fell roughly 13% short of the $27.5 million IBES estimate.

  • Full-Year Guidance Cut

    2026 revenue outlook revised to $101 million-$103 million, with the midpoint representing approximately 15% growth over 2025, reflecting Q3 results, sales team expansion timing, and delayed Development Services contracts.

  • Diagnostic Testing Still Growing

    Diagnostic Testing revenue of $23.055 million grew 16% on a 24% increase in test volumes to 19,400, partly offset by lower average revenue per test as Nodify CDT made up a larger share of lung volume.

  • Losses Narrow, Cash Tightens

    Net loss of $8.032 million improved 8% and Adjusted EBITDA loss of $3.860 million improved 16% year over year; cash was $28.409 million at September 30, down $1.6 million in the quarter after $6.3 million of net ATM proceeds.


Analysis · BDSX · Industrial Applications And Services

Biodesix grew Q3 revenue 10% to $24.0 million, but that landed roughly 13% below the $27.5 million consensus estimate, and management cut full-year 2026 revenue guidance to $101 million-$103 million. The shortfall was execution and timing, not demand: fewer sales reps than planned, heavier primary-care seasonality, and delayed Development Services projects. The company says it has added sales capacity and October was its strongest new-physician acquisition month this year, but the burden of proof now sits on Q4 execution. Cash of $28.4 million, down $1.6 million in the quarter after $6.3 million of ATM proceeds, leaves limited room for another miss.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.1% of the 2636 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BDSX was trading at $18.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $209.3M. The 52-week trading range was $5.26 to $31.97. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BDSX - Latest Insights

BDSX
Nov 06, 2026, 3:24 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $11.61
Real-time Price: $9.00 info
Change: -$2.61 (-22%) info
Market Cap: $226.744M info
BDSX
Nov 05, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.00
Real-time Price: $9.00 info
Change: -$7.00 (-44%) info
Market Cap: $226.744M info
BDSX
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $18.70
Real-time Price: $9.00 info
Change: -$9.70 (-52%) info
Market Cap: $226.744M info
BDSX
Aug 05, 2026, 4:24 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $22.78
Real-time Price: $9.00 info
Change: -$13.78 (-60%) info
Market Cap: $226.744M info
BDSX
May 29, 2026, 5:31 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $16.31
Real-time Price: $9.00 info
Change: -$7.31 (-45%) info
Market Cap: $226.744M info